SMTL ID : 6tcp.4 (3 other biounits)

Crystal structure of the omalizumab Fab Leu158Pro light chain mutant - crystal form II

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.50 Å

Oligo State

hetero-1-1-mer

Ligands

3 x SO4: SULFATE ION(Non-functional Binders)

SO4.1: 4 residues within 4Å: Chain A: Q.41, K.43, K.46, K.49 3 PLIP interactions: 3 interactions with chain A Water bridges: A:Q.41 Salt bridges: A:K.43, A:K.49 SO4.3: 5 residues within 4Å: Chain B: Y.33, R.98, S.100, H.101, Y.102 6 PLIP interactions: 6 interactions with chain B Hydrogen bonds: B:Y.33, B:R.98, B:H.101, B:Y.102 Water bridges: B:Y.102, B:H.107 SO4.5: 2 residues within 4Å: Chain B: R.72, D.74 1 PLIP interactions: 1 interactions with chain B Salt bridges: B:R.72

2 x GOL: GLYCEROL(Non-functional Binders)

GOL.2: 5 residues within 4Å: Chain A: L.58, E.59, S.60, G.61, V.62 1 PLIP interactions: 1 interactions with chain A Hydrogen bonds: A:L.58 GOL.4: 6 residues within 4Å: Chain B: G.32, Y.33, Y.54, S.100, H.101, H.105 2 PLIP interactions: 2 interactions with chain B Hydrogen bonds: B:Y.33, B:H.105

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Mitropoulou, A.N. et al., Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization. Acta Crystallogr.,Sect.F (2020)

Release Date

2020-03-18

Peptides

Omalizumab Fab Leu158Pro light chain mutant: A
Omalizumab Fab Leu158Pro light chain mutant: B

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
E

B
F

Omalizumab Fab Leu158Pro light chain mutant

Omalizumab Fab Leu158Pro light chain mutant

Related Entries With Identical Sequence